Bruder Consulting & Venture Group

Bruder Consulting & Venture Group, based in the US, provides strategic guidance and tactical solutions in regenerative medicine, biologics, and tissue repair, assisting clients in navigating industry challenges. Founded in 2014 and headquartered in New York, Bruder Consulting & Venture Group specializes in consulting services for the regenerative medicine sector. The firm has completed 1 deal, with the most recent deal dated January 13, 2026, when it was acquired by Dark Horse Consulting Group, Inc. , a portfolio company of WestView Capital Partners and Arcline Investment Management.

Financial terms were not disclosed. Bruder Consulting & Venture Group (BCVG) specializes in providing strategic guidance and tactical solutions within the fields of regenerative medicine, biologics, tissue repair, and biomaterials. Their offerings encompass consulting services that leverage extensive industry expertise and Integrated Insights™, addressing the unique challenges faced by clients in medical device, biotech, and cell therapy sectors. BCVG collaborates with a diverse client base, including over 150 partners, approximately 50% of which operate outside the United States.

The firm serves a global market, providing customized solutions tailored to enhance the growth and differentiation of its clients' businesses while helping them navigate complex industry dynamics. Their strategic approach centers on fostering innovation and advancing the commercialization of therapies and products. BCVG's revenue model is structured around transaction-based services, strategic partnerships, and consulting fees accrued from their extensive client engagements. Given the firm's representation in over USD 2 bn in transactions, they facilitate interactions between various stakeholders in the regenerative medicine ecosystem, including medical device manufacturers, biotech firms, and research institutions.

The typical transaction structure may involve B2B relationships, where BCVG provides expert consulting services in exchange for fees based on project scope and duration. Their flagship offerings are associated with high-value consulting projects that require specialized expertise and may involve ongoing partnerships to support the development and commercialization of innovative therapeutics. In January 2026, Dark Horse Consulting Group acquired Bruder Consulting & Venture Group, which will enable the expansion of regenerative medicine capabilities and strengthen support for clients. The acquisition will likely support the development of new products in the regenerative medicine field and facilitate entry into new geographic markets.

Specific markets targeted for expansion have not been disclosed, but the strategy aims to enhance service offerings and client engagement in the evolving landscape of regenerative medicine.